Shattuck Labs (NASDAQ:STTK) Upgraded by Wall Street Zen to Buy Rating

Shattuck Labs (NASDAQ:STTK) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.

A number of other research analysts also recently commented on STTK. Piper Sandler initiated coverage on shares of Shattuck Labs in a research report on Wednesday, January 28th. They set an “overweight” rating and a $15.00 target price on the stock. Wedbush upped their price target on shares of Shattuck Labs from $4.00 to $8.00 and gave the stock an “outperform” rating in a research report on Friday, March 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Shattuck Labs in a research note on Thursday, January 22nd. Needham & Company LLC assumed coverage on shares of Shattuck Labs in a report on Friday, March 6th. They set a “buy” rating and a $25.00 price objective on the stock. Finally, Citigroup boosted their price objective on shares of Shattuck Labs from $4.00 to $7.00 and gave the stock a “neutral” rating in a research note on Friday, March 13th. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $10.50.

Shattuck Labs Trading Down 4.6%

STTK opened at $6.02 on Friday. Shattuck Labs has a 12-month low of $0.69 and a 12-month high of $6.81. The business’s fifty day simple moving average is $4.73 and its 200-day simple moving average is $3.34. The company has a market capitalization of $430.79 million, a price-to-earnings ratio of -7.82 and a beta of 1.55.

Shattuck Labs (NASDAQ:STTK) last released its quarterly earnings data on Thursday, March 5th. The company reported ($0.12) earnings per share for the quarter, meeting the consensus estimate of ($0.12). The firm had revenue of ($1.00) million during the quarter, compared to the consensus estimate of $0.17 million. On average, equities research analysts predict that Shattuck Labs will post -1.48 EPS for the current year.

Hedge Funds Weigh In On Shattuck Labs

Large investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC lifted its position in shares of Shattuck Labs by 27.6% during the first quarter. Acadian Asset Management LLC now owns 257,345 shares of the company’s stock valued at $243,000 after buying an additional 55,687 shares during the last quarter. Squarepoint Ops LLC grew its position in shares of Shattuck Labs by 236.4% in the 4th quarter. Squarepoint Ops LLC now owns 64,785 shares of the company’s stock worth $236,000 after buying an additional 45,525 shares during the last quarter. EP Wealth Advisors LLC bought a new position in shares of Shattuck Labs during the 4th quarter worth approximately $150,000. Invesco Ltd. purchased a new stake in Shattuck Labs during the fourth quarter valued at approximately $103,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Shattuck Labs during the first quarter valued at approximately $81,000. 58.74% of the stock is currently owned by institutional investors.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.